Revolo reinforces '1104 promise with new Phase IIa data

Privately held, venture-funded biotech Revolo Biotherapeutics today announced additional data from its proof of concept, two-week, three-dose, Phase IIa clinical trial evaluating the efficacy, safety, and tolerability of the company’s immune-resetting drug, ‘1104, in adults with active eosinophilic esophagitis (EoE).

Among key observations, Revolo (previously called Immune Regulation) noted that patient reported dysphagia median symptom scores (DSQ) showed a sustained statistically-significant improvement from baseline versus placebo that continued for four weeks after the last dose.

Eosinophil count showed a ~50% statistically-significant reduction from baseline as measured by flow cytometry, and the 8mg ‘1104 showed a statistically-significant ~58% increase in T regulatory cells, that act to suppress inflammatory immune responses, taken from esophageal biopsies.